Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

18.34
+0.02000.11%
Post-market: 18.410.0700+0.38%19:56 EDT
Volume:754.59K
Turnover:13.87M
Market Cap:1.31B
PE:-5.20
High:18.69
Open:18.22
Low:18.07
Close:18.32
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.93
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5300
EPS(LYR):-3.5300
ROE:-60.78%
ROA:-33.92%
PB:4.30
PE(LYR):-5.20

Loading ...

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations

Reuters
·
Dec 08, 2025

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Dec 03, 2025

MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud

Reuters
·
Dec 02, 2025

MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Nov 25, 2025

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 21, 2025

MoonLake price target lowered to $26 from $30 at H.C. Wainwright

TIPRANKS
·
Nov 21, 2025

MoonLake Immunotherapeutics Faces Investor Class Action Over Alleged Securities Fraud

Reuters
·
Nov 19, 2025

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Nov 12, 2025

MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud

Reuters
·
Nov 07, 2025

MoonLake Immunotherapeutics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07, 2025

RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Nov 07, 2025

Stock Track | MoonLake Immunotherapeutics Plummets 5.10% Amid Investor Class Action Lawsuit

Stock Track
·
Nov 07, 2025

Wedbush Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Nov 06, 2025

MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating

TIPRANKS
·
Nov 06, 2025

MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab

TIPRANKS
·
Nov 06, 2025

BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Reuters
·
Nov 05, 2025

MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate

Benzinga
·
Nov 05, 2025

MoonLake Immunotherapeutics - Prices 7.1 Mln Class a Ordinary Shares at $10.50 Each

THOMSON REUTERS
·
Nov 05, 2025

BRIEF-MoonLake Immunotherapeutics Q3 EPS USD -1.1

Reuters
·
Nov 05, 2025

MoonLake Immunotherapeutics reports third quarter 2025 results and announces new clinical trial data

Reuters
·
Nov 05, 2025